Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, such as activated immune cells in autoimmune disease and cancer cells in hematologic and solid tumours.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified health‑care professional should determine the appropriate dosing regimen.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate may be excreted in milk and affect the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Methotrexate is one of the most widely used antimetabolites, offering a balance of efficacy and cost for many autoimmune and oncologic indications. Compared with newer agents such as leflunomide or biologics, methotrexate has a longer safety record but may require more laboratory monitoring for toxicity.

Metoject should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Before administration, the solution may be allowed to reach room temperature, but any unused portion should be discarded according to local regulations.

Metoject is supplied as an injectable solution and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical protocol. Administration is performed by a qualified health‑care professional using aseptic technique and appropriate dosing equipment.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to infection or bleeding, and renal failure. Patients should be monitored regularly for signs of organ dysfunction and instructed to report any new respiratory symptoms, jaundice or unusual bruising.

Metoject is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those with active, uncontrolled infections. Caution is also advised for patients receiving live vaccines or other potent immunosuppressants.